
SK biopharmaceuticals' Q1 earnings solid on strong US cenobamate sales
SK biopharmaceuticals on Friday released robust financial results for the first quarter of 2025, driven by sustained growth in U.S. sales of its epilepsy treatment cenobamate, marketed as Xcopri. The company posted revenue of 144.4 billion won ($102.4 …